诺和诺德口服版减肥药广告遭FDA点名，涉嫌误导性宣传

Core Viewpoint - The FDA has criticized Novo Nordisk for misleading advertising related to its oral weight loss drug, semaglutide, which is the first oral GLP-1 obesity treatment approved in the U.S. [1][2] Group 1: FDA's Concerns - The FDA stated that Novo Nordisk's advertisement constitutes "misbranding" and violates federal law due to misleading claims about the drug's efficacy compared to other GLP-1 weight loss medications [1] - The advertisement suggested that the drug could provide benefits beyond weight loss, such as emotional relief and hope, which have not been proven [2] - The FDA also noted that the advertisement failed to adequately present risk information as required for television drug ads [2] Group 2: Novo Nordisk's Response - Novo Nordisk confirmed receipt of the FDA's letter and expressed its commitment to addressing the regulatory feedback [2] - The company is currently in communication with the FDA regarding the concerns raised about the advertisement [2] Group 3: Legal Actions - Novo Nordisk has filed a lawsuit against Hims & Hers, seeking to prohibit the marketing of compounded versions of semaglutide and claiming damages [2] - Hims & Hers had previously announced plans to launch a low-cost generic version of Novo Nordisk's oral semaglutide but later retracted this decision [3] - The U.S. Department of Health and Human Services has referred Hims & Hers to the Department of Justice for investigation regarding potential violations of the Federal Food, Drug, and Cosmetic Act [3]